阿哌沙班与利伐沙班对腰椎手术后抗凝效果的比较：一项单中心报告。
Comparison of apixaban and rivaroxaban for anticoagulant effect after lumbar spine surgery: a single-center report.
作者信息
Zhang Kun, Zhao Shenghao, Kan Wusheng, Xiao Jun, Pu Feifei, Li Kun
机构信息
Department of Orthopaedics, Wuhan Puai Hospital, Affiliated to Huazhong University of Science & Technology, Wuhan 430033, PR China.
Department of Orthopedics, Wuhan No.1 Hospital, Wuhan Integrated TCM & Western Medicine Hospital, Wuhan 430022, PR China.
出版信息
Future Sci OA. 2018 Mar 14;4(5):FSO297. doi: 10.4155/fsoa-2017-0123. eCollection 2018 Jun.
Abstract
AIM
To compare efficacy and safety of anticoagulants apixaban and rivaroxaban after lumbar spine surgery retrospectively.
METHODS
In this study comprising 480 patients, lower-limb swelling, deep venous thrombosis, pulmonary embolism, blood loss, ecchymosis and D-dimer changes were observed.
RESULTS
The changes in perimeter of the legs were tested, and significant differences were noted 10 cm above the patella, but no significant differences 10 cm below the patella. Twelve thrombotic events occurred in the apixaban group and nine in rivaroxaban group. No significant difference in the incidences of thromboembolic events (p = 1.00). Compared with rivaroxaban, there was significantly less bleeding in the apixaban group (p = 0.03).
CONCLUSION
Apixaban and rivaroxaban were equally effective anticoagulation therapies that exhibited similar preventive effects against postoperative venous thromboembolism after lumbar spine surgery.
摘要
目的
回顾性比较抗凝剂阿哌沙班和利伐沙班在腰椎手术后的疗效和安全性。
方法
本研究纳入480例患者，观察下肢肿胀、深静脉血栓形成、肺栓塞、失血量、瘀斑及D-二聚体变化。
结果
对腿部周长变化进行检测，发现髌骨上方10厘米处有显著差异，但髌骨下方10厘米处无显著差异。阿哌沙班组发生12例血栓事件，利伐沙班组发生9例。血栓栓塞事件发生率无显著差异（p = 1.00）。与利伐沙班相比，阿哌沙班组出血明显较少（p = 0.03）。
结论
阿哌沙班和利伐沙班是同样有效的抗凝治疗药物，对腰椎手术后的术后静脉血栓栓塞具有相似的预防作用。
相似文献
1
Comparison of apixaban and rivaroxaban for anticoagulant effect after lumbar spine surgery: a single-center report.阿哌沙班与利伐沙班对腰椎手术后抗凝效果的比较：一项单中心报告。
Future Sci OA. 2018 Mar 14;4(5):FSO297. doi: 10.4155/fsoa-2017-0123. eCollection 2018 Jun.
2
Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.与华法林相比，直接口服Xa因子抑制剂在病态肥胖患者中的疗效和安全性：一项单中心图表数据回顾性分析
Lancet Haematol. 2019 Jul;6(7):e359-e365. doi: 10.1016/S2352-3026(19)30086-9. Epub 2019 May 24.
3
Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis.阿哌沙班与利伐沙班预防静脉血栓栓塞症患者复发性静脉血栓栓塞和不良出血事件的有效性及安全性：一项基于人群的回顾性队列分析。
Lancet Haematol. 2019 Jan;6(1):e20-e28. doi: 10.1016/S2352-3026(18)30191-1. Epub 2018 Dec 14.
4
Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis.不同抗凝药物对关节置换术后患者并发症预防的影响：一项网状Meta分析。
Medicine (Baltimore). 2017 Oct;96(40):e8059. doi: 10.1097/MD.0000000000008059.
5
Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.口服利伐沙班对比标准抗凝治疗有症状的深静脉血栓形成的安全性和有效性（XALIA）：一项国际前瞻性非干预性研究。
Lancet Haematol. 2016 Jan;3(1):e12-21. doi: 10.1016/S2352-3026(15)00257-4. Epub 2015 Dec 8.
6
Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.采用混合治疗比较的荟萃分析方法评估口服抗凝剂用于静脉血栓栓塞症的长期治疗。
Clin Ther. 2014 Oct 1;36(10):1454-64.e3. doi: 10.1016/j.clinthera.2014.06.033. Epub 2014 Aug 3.
7
Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.阿哌沙班与其他口服抗凝剂用于静脉血栓栓塞初始治疗及预防复发的成本效益分析
Clin Ther. 2016 Mar;38(3):478-93.e1-16. doi: 10.1016/j.clinthera.2016.01.020. Epub 2016 Feb 26.
8
Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.直接Xa因子抑制剂（利伐沙班和阿哌沙班）与依诺肝素用于全膝关节置换术后预防静脉血栓栓塞：6项随机临床试验的荟萃分析
Thromb Res. 2015 May;135(5):816-22. doi: 10.1016/j.thromres.2015.02.008. Epub 2015 Feb 12.
9
10
Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.新型口服抗凝药阿哌沙班、达比加群、依度沙班和利伐沙班在静脉血栓栓塞症初始及长期治疗与预防中的比较：系统评价与网状Meta分析
PLoS One. 2015 Dec 30;10(12):e0144856. doi: 10.1371/journal.pone.0144856. eCollection 2015.
引用本文的文献
1
A Protocol for Venous Thromboembolism Prophylaxis in Elective Spine Surgery: A Retrospective Evaluation of a Single-Center Experience.一项择期脊柱手术中静脉血栓栓塞预防方案：单中心经验的回顾性评估
Cureus. 2025 Jun 3;17(6):e85297. doi: 10.7759/cureus.85297. eCollection 2025 Jun.
2
Role of Direct Oral Anticoagulants for Post-operative Venous Thromboembolism Prophylaxis.直接口服抗凝剂在术后静脉血栓栓塞预防中的作用。
Eur Cardiol. 2022 May 13;17:e11. doi: 10.15420/ecr.2021.55. eCollection 2022 Feb.
3
Perioperative Anticoagulation Management in Spine Surgery: Initial Findings From the AO Spine Anticoagulation Global Survey.脊柱手术围手术期抗凝管理：AO脊柱抗凝全球调查的初步结果
Global Spine J. 2020 Aug;10(5):512-527. doi: 10.1177/2192568219897598. Epub 2020 Apr 17.
4
Venous Thromboprophylaxis in Spine Surgery.脊柱手术中的静脉血栓预防
Global Spine J. 2020 Jan;10(1 Suppl):65S-70S. doi: 10.1177/2192568219858307. Epub 2019 Jun 19.
5
McConnell's sign in a patient with pulmonary embolism.一名肺栓塞患者的麦康奈尔征。
BMJ Case Rep. 2018 Nov 28;11(1):e227576. doi: 10.1136/bcr-2018-227576.
本文引用的文献
1
Thromboprophylaxis With Apixaban in Patients Undergoing Major Orthopedic Surgery: Meta-Analysis and Trial-Sequential Analysis.阿哌沙班用于大型骨科手术患者的血栓预防：荟萃分析和试验序贯分析
Clin Med Insights Blood Disord. 2017 May 8;10:1179545X17704660. doi: 10.1177/1179545X17704660. eCollection 2017.
2
Overview of Current Evidence on the Impact of the Initial High Dose of the Direct Factor Xa Inhibitor Rivaroxaban on Thrombus Resolution in the Treatment of Venous Thromboembolism.直接Xa因子抑制剂利伐沙班初始高剂量对静脉血栓栓塞症治疗中血栓溶解影响的当前证据概述
Int Heart J. 2017 Feb 7;58(1):6-15. doi: 10.1536/ihj.16-617. Epub 2017 Jan 24.
3
Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis.新型抗凝剂预防髋膝关节置换术后静脉血栓栓塞的安全性和有效性：一项荟萃分析。
J Arthroplasty. 2017 Feb;32(2):645-652. doi: 10.1016/j.arth.2016.09.033. Epub 2016 Oct 5.
4
Risk factors associated with venous thromboembolism in patients undergoing spine surgery.脊柱手术患者静脉血栓栓塞的相关危险因素。
J Neurosurg Spine. 2017 Jan;26(1):90-96. doi: 10.3171/2016.6.SPINE1656. Epub 2016 Sep 2.
5
Risk Factors for Postoperative Venous Thromboembolism in Orthopaedic Spine Surgery, Hip Arthroplasty, and Knee Arthroplasty Patients.骨科脊柱手术、髋关节置换术和膝关节置换术患者术后静脉血栓栓塞的危险因素
Bull Hosp Jt Dis (2013). 2015 Jul;73(3):198-203.
6
Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review.阿哌沙班用于预防和治疗深静脉血栓形成及肺栓塞：一项循证综述
Ther Clin Risk Manag. 2015 Aug 26;11:1273-82. doi: 10.2147/TCRM.S68010. eCollection 2015.
7
Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.直接Xa因子抑制剂（利伐沙班和阿哌沙班）与依诺肝素用于全膝关节置换术后预防静脉血栓栓塞：6项随机临床试验的荟萃分析
Thromb Res. 2015 May;135(5):816-22. doi: 10.1016/j.thromres.2015.02.008. Epub 2015 Feb 12.
8
Risk factors for venous thromboembolism after spine surgery.脊柱手术后静脉血栓栓塞的危险因素。
Medicine (Baltimore). 2015 Feb;94(5):e466. doi: 10.1097/MD.0000000000000466.
9
Decreased incidence of venous thromboembolism after spine surgery with early multimodal prophylaxis: Clinical article.脊柱手术后早期多模式预防可降低静脉血栓栓塞发生率：临床文章。
J Neurosurg Spine. 2014 Oct;21(4):677-84. doi: 10.3171/2014.6.SPINE13447. Epub 2014 Aug 8.
10
An evidence-based clinical guideline for the use of antithrombotic therapies in spine surgery.脊柱外科抗血栓治疗的循证临床指南。
Spine J. 2009 Dec;9(12):1046-51. doi: 10.1016/j.spinee.2009.09.005.
Zotero 插件